Expression of VEGF, VEGF-C and VEGFR-2 in in situ and invasive SCC of cervix

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 2, 2010, Pages 411-423

  Jach, Robert ^a   Dulinska Litewka, Joanna ^a   Laidler, Piotr ^a   Szczudrawa, Andrzej ^a   Kopera, Andrzej ^a   Szczudlik, Łukasz ^a   Pawlik, Michał ^a   Zaja̧c, Krzysztof ^a   Mak, Monika ^a   Basta, Antoni ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cervical cancer; Pathology; Vascular endothelial growth factor; VEGF C; VEGF R2

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER INVASION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOPHYSIOLOGY; PREGNANCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77954480004     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e101     Document Type: Article

References (52)

1. McIndoe W. A., M. R. McLean, R. W. Joneand, P. R. Mullins: The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 64, 451-8 (1984) (Pubitemid 14013986)
2. Shafi M. I., D. M. Luesley: Management of low grade lesions: Follow-up or treat? Baillieres Clin Obstet Gynaecol 9, 121-31 (1995)
3. Chilvers C.: Oral contraceptives and cancer. Lancet 344, 1378-9 (1994) (Pubitemid 24365306)
4. Waggoner S. E.: Cervical cancer. Lancet 361, 2217-25 (2003) (Pubitemid 36782559)
5. Zheng T., T. R. Holford, Z. Ma, Y. Chen, W. Liu, B. A. Ward, P. Boyle: The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol 2, 252-8 (1996) (Pubitemid 26137104)
6. Basta A., K. Adamek, K. Pityñski: Intraepithelial neoplasia and early stage vulvar cancer. Epidemiological, clinical and virological observations. Eur J Gynaecol Oncol 20(3), 209-11 (1999)
7. Jach R., A. Basta: Pharmacological immunomodulation in CIN and HPV infection. Scien. Mat. 2nd European Congress for Colposcopy and Cervical Pathology 170 (2001)
8. Munoz N., X. Castellsague, Berrington de Gonzalez, Gissmann L.: HPV in the etiology of human cancer. Vaccine 24(Suppl. 3), 1-10 (2006)
9. zur Hausen H.: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2, 342-50 (2002) (Pubitemid 37328947)
10. Folkman J., D. Hanahan: Switch to the angiogenic phenotype during tumorigenesis. Princes Takamatsu Symp. 22, 339-47 (1991)
11. Folkman J.: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285, 1182-1186 (1971)
12. Weidner N., J. P. Semple, W. R. Welch, J. Folkman: Tumor angiogenesis and metastatic correlation in invasive breast carcinoma. N Engl J Med 324, 1-8 (1991)
13. Ferrara N., H. Heinsohn, C. E. Waldner, S. Bunting, G. R. Thomas: The regulation of blood vessel growth by vascular endothelial growth factor. Ann NY Acad Sci 752, 246-56 (1995)
14. Gustafsson T., H. Ameln, H. Fischer, C. J. Sundberg, J. A. Timmons, E. Jansson: VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise. J Appl Physiol 98(6), 2137-46 (2005) (Pubitemid 40726908)
15. Olofsson B., K. Pajusola, A. Kaipainen, G. von Euler, V. Joukov, O. Saksela, A. Orpana, R. F. Pettersson, K. Alitalo, U. Eriksson: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93, 2576-2581 (1996) (Pubitemid 26104389)
16. Joukov V., K. Pajusola, A. Kaipainen, D. Chilov, I. Lahtinen, E. Kukk, O. Saksela, N. Kalkkinen, K. Alitalo: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15, 1751-1758 (1996)
17. Achen M. G., M. Jeltsch, E. Kukk, T. Makinen, A. Vitali, A. F. Wilks, K. Alitalo, S. A. Stacker: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95, 548-553 (1998) (Pubitemid 28083780)
18. Zheng Y. M., H. Murakami, M. Takahashi, A. Yamauchi, S. Kiba, N. Yamaguchi, K. Yabana, K. Alitalo, M. Shibuya: Chimeric VEGF-E (NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 26:2019-2026 (2006) (Pubitemid 44253783)
19. Maglione D., V. Guerriero, G. Viglietto, M. G. Ferraro, O. Aprelikova, K. Alitalo, S. Del Vecchio, K. J. Lei, J. Y. Chou M. G. Persico: Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8, 925-931 (1993) (Pubitemid 23087424)
20. Poltorak Z, T. Cohen, G. Neufeld: The VEGF splice variants: properties, receptors, and usage fort the treatment of ischemic diseases. Herz 25:126-129, 2000 (Pubitemid 30238979)
21. Stacker S. A., M. G. Achen, L. Jussila, M. E. Baldwin, K. Alitalo: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2, 573-583 (2002) (Pubitemid 37328924)
22. Liotta L. A., P. S. Steeg, W. G. Stetler-Stevenson: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-36 (1991) (Pubitemid 121001258)
23. Toi M., S. Kondo, H. Suzuki, Y. Yamamoto, K. Inada, T. Imazama: Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77, 1101-1106 (1996) (Pubitemid 26080900)
24. Obermair A., E. Kucera, K. Mayerhofer, P. Speiser, M. Seifert, K. Czerwenka: Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with diseasefree survival. Int J Cancer 74, 455-458 (1997) (Pubitemid 27400169)
25. White J. D., P. W. Hewett, D. Kosuge, T. McCulloch, B. C. Enholm, J. Carmichael, J. C. Murray: Vascular endothelial growth factor-D expression is an independent prognostic marker in colorectal carcinoma. Cancer Res 62:1669-75 (2002) (Pubitemid 34408487)
26. Dulinska J., P. Laidler, M. Labedz: Comparative analysis of prostatic acid phosphatase and prostate-specific antigen mRNA levels in hyperplastic prostate stimulated with steroid hormones and growth factors. Acta Biochim Pol: 49(2), 357-68 (2002) (Pubitemid 135686782)
27. Dulinska J., D. Gil, J. Zagajewski, J. Hartwich, M. Bodzioch, A. Dembinska-Kiec, T. Langmann, G. Schmitz, P. Laidler: Different effect of beta carotene on proliferation of prostate cancer cells. BBA-Molecular Basis of Disease 1740, 189-201 (2005) (Pubitemid 40798229)
28. Gabert J., E. Beillard, V. H. J. van der Velden, W. Bi, D. Grimwade, N. Pallisgaard, G. Barbany, G. Cazzaniga, J. M. Cayuela, H. Cave, F. Pane, J. L. E. Aerts, D. de Micheli, X. Thirion, V. Pradel, M. Gonzalez, S. Viehmann, M. Malec, G. Saglio, J. M van Dongen.: Standardisation and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia - a Europe against cancer Program. Leukemia 17(12), 2318-2357 (2003) (Pubitemid 38072573)
29. M. Macabeo-Ong, D. G. Ginzinger, N. Dekker, A. McMillan, J. A. Regezi, D. T. W. Wong, R. C. K. Jordan: Effect of Duration of Fixation on Quantitative Reverse Transcription Polymerase Chain Reaction Analyses. Mod Pathol, 15, 979-987 (2001)
30. Peterson L. A.: A simplification of the protein assay method of Lowry which is more generally applicable. Anal Biochem 83, 346-356 (1977)
31. Laemmli U. K.: Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature 227, 680-685 (1970)
32. Sedmak J. J., S. E. Grossberg: A rapid, sensitive and versatile assay for protein using Coomassie Brilliant Blue G-250. Anal Biochem 79, 544-52 (1977) (Pubitemid 8105123)
33. Clifford G., R. Rashida, S. Franceschi, J. Smith, G. Gough, J. Pimenta: Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer. Cancer Epidemiol Biomarkers Prevent Vol. 14, 1157-1164 (2005) (Pubitemid 40656461)
34. Cuzick J, C. Clavel, K. U. Petry, C. J. Meijer, H. Hoyer, S. Ratnam: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 1, 119(5), 1095-1101 (2006) (Pubitemid 44116919)
35. Tischer E., R. Mitchel, T. Hartman, M. Silva, D. Gospodarowicz, J. C. Fiddes, J. A. Abraham: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 25, 266(18), 11947-54 (1991)
36. van Trappen P. O. et all: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201, 544-54 (2003) (Pubitemid 38256403)
37. Basta A.: Colposcopy in pregnancy. Cervix, Ed. Singer A. (2007)
38. Smith J. S., L. Lindsay, J. Keys, B. Hoots, R. L. Winer, S. Franceschi: HPV type distribution in invasive cervical cancer and high-grade cervical neoplasia: an update of meta-analyses and identification of global data gaps. Br J Cancer (2006)
39. Terlikowski S., A. Lenczewski, M. Sulkowska et all: Tissue expression of VEGF as a prognostic factor in early cervical squamous cells carcinoma. Folia Histochem Cytobiol 39, (suppr 2), 112-13 (2001) (Pubitemid 34070783)
40. Ueda M., Y. Terai, Y. Yamashita et all: Correlation between vascular endothelial growth factor - C expression and invasion phenotype in cervical carcinomas. Int J Cancer 98, 335-43 (2002) (Pubitemid 34188675)
41. Fosslien E.: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 31, 325-48 (2001) (Pubitemid 32988657)
42. Kim M. H., S. S. Seo, Y. S. Song et all: Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol Oncol 90, 83-90 (2003)
43. Bequet-Romero M., O. Lopez-Ocejo: Angiogenesis modulator expression in culture cell lines positive for HPV-16 oncoprotein. Biochem Biophys Res Commun 277, 55-61 (2000)
44. Lopez-Ocejo O., A. Viloria-Petit, M. Bequet-Romero et all: Oncogens and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19, 4611-20 (2000)
45. Hernandez P., N. Merino, O. Lopez-Ocejo et all: A Mouse fibroblast cell model to study human papillomavirus-associated tumorigenesis. Biochem Biophys Res Commun 270, 119-24 (2000) (Pubitemid 30440402)
46. Smith-McCune K., Y. H. Zhu, D. Hanahan et all: Crossspecies comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 57, 1294-300 (1997) (Pubitemid 27152554)
47. Rak J., G. Klement: Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 19, 93-96 (2000) (Pubitemid 32004698)
48. Rak J., Y. Mitsuhashi, C. Sheehan, A. Tamir, A. Viloria-Petit, J. Filmus, S. J. Mansour, N. G. Ahn, R. S. Kerbel: Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in rastransformed epithelial cells and fibroblasts. Cancer Res 60, 490-498 (2000) (Pubitemid 30070780)
49. Jain R. K., L. L. Munn, D. Fukumura: Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2, 266-276 (2002) (Pubitemid 37328780)
50. Karpanen T., M. Egeblad, M. J. Karkkainen, H. Kubo, S. Yla-Herttuala, M. Jaattela, K. Alitalo: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61, 1786-1790 (2001) (Pubitemid 32691984)
51. Mandriota S. J., L. Jussila, M. Jeltsch, A. Compagni, D. Baetens, R. Prevo, S. Banerji, J. Huarte, R. Montesano, D. G. Jackson, L. Orci, K. Alitalo, G. Christofori, M. S. Pepper: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis. EMBO J 20, 672-682 (2001) (Pubitemid 32167632)
52. Stacker S. A., M. E. Baldwin, M. G. Achen: The role of tumor lymphangiogenesis in metastatic spread. FASEB J 16, 922-934 (2002) (Pubitemid 34753498)